Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

Annals of Hematology

Volumn 94, Issue 7, 2015, Pages 1127-1138

  Medeiros, Bruno C ^a   Satram Hoang, Sacha ^b   Hurst, Deborah ^c   Hoang, Khang Q ^b   Momin, Faiyaz ^b   Reyes, Carolina ^c,d  

^a STANFORD UNIVERSITY   (United States)

^b QD Research Inc   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myeloid leukemia; Chemotherapy; Elderly; Stem cell transplantation; Survival; Treatment

Indexed keywords

AGED; CANCER REGISTRY; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICARE; MORTALITY; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICARE; RETROSPECTIVE STUDIES; SEER PROGRAM; STATISTICS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84939932841     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2351-x     Document Type: Article

References (44)

1. Yamamoto JF, Goodman MT (2008) Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 19:379–390
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
3. National Cancer Institute. SEER Stat Fact Sheets: Acute Myeloid Leukemia. Bethesda, MD:. Available from URL: http://seer.cancer.gov/statfacts/html/amyl.html. Accessed November 2013
4. Appelbaum FR, Gundacker H, Head DR et al (2006) Age and acute myeloid leukemia. Blood 107:3481–3485
5. Kantarjian H, O’Brien S, Cortes J et al (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090–1098
6. Lang K, Earle CC, Foster T et al (2005) Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 22:943–955
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 2.2014. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/aml.pdf. Accessed 30 Aug 2014
8. Williams JP, Handler HL (2000) Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia. Am J Manag Care 6:S975–S985
9. Herr AL, Labopin M, Blaise D et al (2007) HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 21:129–135
10. Storb R (2007) Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 20:85–90
11. Juliusson G (2011) Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 11(Suppl 1):S54–S59
12. Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179–4187
13. Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720–2726
14. Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067
15. Gross CP, Murthy V, Li Y et al (2004) Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 96:1063–1069
16. Mengis C, Aebi S, Tobler A et al (2003) Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21:3933–3939
17. Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3–IV-18
18. Potosky AL, Riley GF, Lubitz JD et al (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732–748
19. Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951
20. Davidoff AJ, Tang M, Seal B et al (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28:2191–2197
21. Klabunde CN, Legler JM, Warren JL et al (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17:584–590
22. Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
23. Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-medicare data to identify chemotherapy use. Med Care 40:IV-55-–IV-61
24. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499
25. Kurth T, Walker AM, Glynn RJ et al (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262–270
26. Rosenbaum PR, Rubin DB (1983) The central rose of the propensity score in observational studies for causal effects. Biometrika 70:41–55
27. Lowenberg B, Zittoun R, Kerkhofs H et al (1989) On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268–1274
28. Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677
29. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–569
30. Dombret H, Seymour JF, Butrym A et al (2014) Results of a Phase 3, Multicenter, Randomized, Open-Label Study of Azacitidine (AZA) vs Conventional Care Regimens (CCR). In: Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). 19th Congress of the European Hematology Association Milan, Italy
31. Oran B, Weisdorf DJ (2012) Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97:1916–1924
32. Estey E, de Lima M, Tibes R et al (2007) Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109:1395–1400
33. Wang M, Burau KD, Fang S et al (2008) Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 113:3231–3241
34. Shavers VL, Brown ML (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94:334–357
35. Aizer AA, Chen MH, McCarthy EP et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869–3876
36. Juliusson G, Billstrom R, Gruber A et al (2006) Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 20:42–47
37. Buchner T, Hiddemann W, Berdel W et al (2002) Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 6:46–59, discussion 86-7
38. Nabhan C, Smith SM, Helenowski I et al (2012) Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 156:196–204
39. Oxnard GR, Fidias P, Muzikansky A et al (2007) Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol 2:1029–1035
40. Dale DC (2003) Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. J Support Oncol 1:11–17
41. Dohner H, Lubbert M, Fiedler W et al (2014) Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 124:1426–1433
42. Lancet JE, Cortes JE, Hogge DE et al (2014) Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239–3246
43. Burnett AK, Russell NH, Hills RK et al (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924–3931
44. Castaigne S, Pautas C, Terre C et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379:1508–1516